Switch theme
Sign up to access all valuation multiples
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
1982
75
Last FY Revenue $26.5M
Last FY EBITDA $1.1M
$68.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, ImmuCell achieved revenue of $26.5M and an EBITDA of $1.1M.
ImmuCell expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ImmuCell valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $26.5M | XXX | XXX | XXX |
| Gross Profit | XXX | $7.9M | XXX | XXX | XXX |
| Gross Margin | XXX | 30% | XXX | XXX | XXX |
| EBITDA | XXX | $1.1M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 4% | XXX | XXX | XXX |
| EBIT | XXX | -$1.6M | XXX | XXX | XXX |
| EBIT Margin | XXX | -6% | XXX | XXX | XXX |
| Net Profit | XXX | -$2.2M | XXX | XXX | XXX |
| Net Margin | XXX | -8% | XXX | XXX | XXX |
| Net Debt | XXX | $6.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ImmuCell's stock price is $6.
ImmuCell has current market cap of $57.9M, and EV of $68.0M.
See ImmuCell trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $68.0M | $57.9M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ImmuCell has market cap of $57.9M and EV of $68.0M.
ImmuCell's trades at 2.6x EV/Revenue multiple, and 63.7x EV/EBITDA.
Equity research analysts estimate ImmuCell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ImmuCell's P/E ratio is not available.
See valuation multiples for ImmuCell and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $57.9M | XXX | $57.9M | XXX | XXX | XXX |
| EV (current) | $68.0M | XXX | $68.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 63.7x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -41.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -26.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -630.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialImmuCell's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
ImmuCell's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ImmuCell's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ImmuCell and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 4% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 36% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ImmuCell acquired XXX companies to date.
Last acquisition by ImmuCell was XXXXXXXX, XXXXX XXXXX XXXXXX . ImmuCell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ImmuCell founded? | ImmuCell was founded in 1982. |
| Where is ImmuCell headquartered? | ImmuCell is headquartered in United States of America. |
| How many employees does ImmuCell have? | As of today, ImmuCell has 75 employees. |
| Who is the CEO of ImmuCell? | ImmuCell's CEO is Mr. Michael F. Brigham. |
| Is ImmuCell publicy listed? | Yes, ImmuCell is a public company listed on NAS. |
| What is the stock symbol of ImmuCell? | ImmuCell trades under ICCC ticker. |
| When did ImmuCell go public? | ImmuCell went public in 1995. |
| Who are competitors of ImmuCell? | Similar companies to ImmuCell include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of ImmuCell? | ImmuCell's current market cap is $57.9M |
| Is ImmuCell profitable? | Yes, ImmuCell is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
